Panagiotis Roussos, MD, MS, PhD

Research

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:61

Article:174

Review Article:8

Comment/Debate:10

Letter:3

Editorial:1

Chapter:6

Recent Artifacts

• Comment on: What genes are differentially expressed in individuals with schizophrenia? A systematic review
• Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains
• Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae
• A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility
• Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome
• Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression among Adults in the US Veterans Affairs Health Care System
• Erratum: Analysis of Transcriptional Variability in a Large Human iPSC Library Reveals Genetic and Non-genetic Determinants of Heterogeneity (Cell Stem Cell (2017) 20(4) (518–532.e9), (S1934590916304015), (10.1016/j.stem.2016.11.005))
• Identification of shared and differentiating genetic architecture for autism spectrum disorder, attention-deficit hyperactivity disorder and case subgroups
• Impact of schizophrenia GWAS loci converge onto distinct pathways in cortical interneurons vs glutamatergic neurons during development
• Population-level variation in enhancer expression identifies disease mechanisms in the human brain

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Roussos during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.